Hyperion Therapeutics, Inc. Company Profile
Hyperion Therapeutics is a privately held pharmaceutical company focused on the development of therapies that address critical unmet needs and underserved patient populations in the areas of gastroenterology and hepatology. Hyperion and Ucyclyd Pharma, Inc., a subsidiary of Medicis Pharmaceutical Corporation, entered into a collaboration agreement for HPN-100 (glycerol phenylbutyrate) in August 2007. Under the terms of the agreement, Hyperion is conducting ongoing research and development of HPN-100 for urea cycle disorders, hepatic encephalopathy, and other forms of hyperammonemia. Hyperion is headquartered in South San Francisco, CA. For additional information, visit www.hyperiontx.com.
News Articles
Hyperion Therapeutics Inc. (NASDAQ:HPTX) raised $50 million through the sale of 5 million shares at $10 in an IPO. The price values the company at about $153.7 million. Leerink; Cowen; and Needham wer...
Hyperion Therapeutics Inc. (South San Francisco, Calif.) amended its IPO and now plans to sell 4.2 million shares at $11-$13 per share. A $12 price would raise $50 million and value the company at $17...
Hyperion raises $59.7M in bumped-up follow-on
Hyperion Therapeutics Inc. (NASDAQ:HPTX) raised $59.7 million through the sale of 2.9 million shares at $20.75 in a bumped-up follow-on underwritten by Leerink; Cowen; Needham; and JMP Securities. Hyp...
FDA extended the PDUFA date by three months for an NDA from Hyperion Therapeutics Inc. (NASDAQ:HPTX) for Ravicti glycerol phenylbutyrate for the management of chronic urea cycle disorders in patients...
Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections
Cary, NC (PRWEB) February 27, 2013 PharmaDirections congratulates Hyperion Therapeutics on achieving a NDA approval for their RAVICTI⢠(glycerol phenylbutyrate) Liquid for Treatment of Urea C...
Hyperion Therapeutics: IPO offering for $50 million
Hyperion Therapeutics announced the pricing of its initial public offering of 5,000,000 shares of its common stock at $10.00 per share, before underwriting discounts and commissions. All of the common...
Market Bets On Approval For Hyperion's Ravicti On FDA's 'Hint'
By Brian L. Wilson:There were a lot of very bullish moves in the biotech sector last week, including a particularly huge rally in Hyperion Therapeutics (NASDAQ: HPTX) which drove the stock up about 33...
Cowen Maintains An Outperform On Hyperion Therapeutics
By Ben Yoffe:In a research note issued last week, Cowen and Company analysts maintained coverage with an "Outperform" rating on Hyperion Therapeutics (HPTX), and highlighted the important issues from...
Drugs and Medications
None
PubMed Articles
Hyperspectral imaging sensors suffer from spectral and spatial misregistrations due to optical-system aberrations and misalignments. These artifacts distort spectral signatures that are specific to ta...
Karst rocky desertification is a process of land desertification associated with human disturbances of the fragile karst ecosystems. The fractional cover of photosynthetic vegetation (PV) and exposed...
Clinical Trials
None
Companies
Hyperion Therapeutics is a privately held pharmaceutical company focused on the development of therapies that address critical unmet needs and underserved patient populations in t...
Hyperion Adjusters Limited is a City based practice which commenced trading on May 1, 2003 and is owned by both the staff and an investor. The firm is primarily drawn from those professional and suppo...
Wellstat Biologics Corporation
Wellstat Biologics™ Corporation is a privately-held company located in Gaithersburg, Maryland. Dedicated to the discovery, development and commercialization of biological agents that meet the challe...
More Information about "Hyperion Therapeutics, Inc." on BioPortfolio
We have published hundreds of Hyperion Therapeutics, Inc. news stories on BioPortfolio along with dozens of Hyperion Therapeutics, Inc. Clinical Trials and PubMed Articles about Hyperion Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Hyperion Therapeutics, Inc. Companies in our database. You can also find out about relevant Hyperion Therapeutics, Inc. Drugs and Medications on this site too.
